Welcome back to the end of the week wrap up where we compile and share the latest cannabis news and education.
We're only a couple of weeks into the new year and already firing on all cylinders. From a technology standpoint, we've got some great things in the pipeline to better serve our customers and network of health professionals. So if you're been following along, we're looking forward to sharing the updates with you in the coming weeks.
With that said, here are some of the top articles our team discovered this week on everything cannabis:
- As more states have moved to legalise cannabis, advocates have pushed for updated guidelines to make it so a person’s marijuana record doesn’t add criminal history points that could lead to enhanced sentences.
- The new USSC proposal doesn’t seek to remove cannabis convictions as a criminal history factor entirely, but it would revise commentary within the guidelines to “include sentences resulting from possession of cannabis offences as an example of when a downward departure from the defendant’s criminal history may be warranted.”
- The commission is seeking public comment on the proposed revision, specifically inviting input on whether there is an alternative approach it should consider for addressing sentences for possession of cannabis
Key Takeaway: In order to prevent a person's cannabis use from accruing criminal history points that could result in longer sentences, supporters have campaigned for updated guidelines.
- Researchers at Michigan Medicine surveyed 1,661 adults last spring with chronic pain who lived in one of the 36 states with active medical cannabis programs and Washington, D.C.?
- Out of those people who said they consumed cannabis to help alleviate pain, more than half reported that the drug led to lower use of prescription opioids, nonopioids and over-the-counter pain medications.
- About 39 percent of people who reported using cannabis to treat chronic pain said it led to them taking part in less physical therapy and 19 percent said it led to them meditating less in order to manage their pain, according to the study.
Key Takeaway: The fact that patients report substituting cannabis for pain medications so much underscores the need for research on the benefits and risk of using cannabis for chronic pain.
- The firm put the facility on the market in October 2022 as part of a plan to consolidate the majority of its operations in Mildura
- The parties have come to terms on the sale of the Southern facility’s land and business assets, the licensing of certain Cann genetics, and the provision of services from Cann to Sativite to facilitate the transfer of commercial operations.
- The firms have also agreed for Cann to provide access rights to certain genetic strains, for a total fee of $480,000 payable over two years from the land settlement date.?
Key Takeaway: Synergies of values and ethics demonstrates the industry leaders willinging to collaborate and innovate for the betterment of the cannabis sector
- This meta-analysis of 20 randomised controlled studies considered the effect of positive media attention on patient expectations for pain relief from cannabis products.
- The active treatments used in these studies included two main cannabinoids in cannabis, delta-9-tetrahydrocannabinol (THC) or cannabidiol (CBD), and the prescription drugs nabilone (Cesamet), dronabinol (Marinol, Syndros), and nabiximols (Sativex).
- Researchers found that participants receiving active treatment and participants receiving placebo reported similar levels of pain relief.
Key Takeaway: A clinical trial is not real life. Chronic pain is notoriously difficult to treat. And the more effective a drug is at treating pain, the greater the likelihood of side effects and other unwanted consequences, such as dependency and addiction.?
- Rather than playing the waiting game, cannabis business leaders should take a proactive approach to compliance, whether they want access to the global cannabis market or are just looking to increase revenue at home.
- Deciding to “Go GMP” could potentially have lasting financial impacts on cannabis businesses willing to do the work. The GMP stamp of approval on products undoubtedly creates the impression of an elevated brand compared to lower-quality competitors with no certifications to boast about.
- Companies not preparing to enter the global market could find it hard to compete with other cannabis brands that have followed these standards since legalisation.
Key Takeaway: A set of rules known as good manufacturing practice (GMP) guarantees that pharmaceuticals satisfy high quality standards that consumers, businesses, and governments can rely on. These procedures touch on all areas of creating a product.
That concludes our weekly wrap up. We hope you all had a wonderful first week back in business.
Let us know what you think!
Disclaimer: All articles shared are credited to its rightful owners. Information shared on this page is for educational purposes only. We are not here to promote the use of cannabis. If you do intend to consume cannabis, we advise you to speak to your local general practitioner for more information and guidance.
